☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC March Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Zoledronic acid infusion (Aclasta®) has been accepted for restricted use in patients who are unsuitable for or unable to tolerate oral treatment options for osteoporosis.

Salmeterol / fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler®) was rejected for the treatment of patients with chronic obstructive airways disease (COPD), with a forced expiration volume in 1 second (FEV1) 50 to <60% predicted normal. The manufacturer did not present a sufficiently robust economic case to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.

Share 'SMC March Update' by emailShare 'SMC March Update' on FacebookShare 'SMC March Update' on TwitterShare 'SMC March Update' on LinkedInShare 'SMC March Update' on reddit


No Comments to “SMC March Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.